Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

Treatment with ribociclib plus endocrine therapy led to a statistically and clinically meaningful improvement in invasive disease-free survival among patients with hormone receptor–positive/HER2-negative early breast cancer compared with endocrine therapy alone, meeting the primary end point of the phase 3 NATALEE trial.

Related Keywords

University Of Chicago ,Illinois ,United States ,California ,American ,Rita Nanda ,Los Angeles ,Dennisj Slamon ,University Of Chicago Medicine ,Clinical Translational Research ,American Society Of Clinical Oncology Annual Meeting ,Jonsson Comprehensive Cancer Center ,Women Cancer Research Program ,Breast Oncology Program ,Clinical Oncology Annual ,Translational Research ,Cancer Research Program ,Comprehensive Cancer Center ,Recurrence Score ,Chicago Medicine ,2023 Asco Annual Meeting ,Breast Cancer ,Ribociclib ,Endocrine Therapy ,Her2 Negative Breast Cancer ,Phase 3 Natalee Trial Nct03701334 ,